HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $66 to $68.
Filings · News reference
Tango Therapeutics Files Prospectus For Up To $400M Common Stock Offering
Up to $400,000,000Common StockWe have previously entered into a Sales Agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, dated November 21, 2025, relating to the sale of shares of our
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $32 to $35.
8-K filing — Tango Therapeutics, Inc. (TNGX)
Filed: 2026-08-11 AccNo: 0001193125-26-344997 Size: 154 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits